Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.

Market Cap	$7.03M	P/E Ratio	NaN
52W High	$10.16	52W Low	$2.08
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	56.3%	52W Position	6.2%
Overall Score	53	Value Score	60
Quality Score	47	Technical Score	54

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMRA	$2.58	0.00%	15.10K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMRA	$2.58	0%	15.10K
3
4
5
6

BMRA

BMRA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Biomerica Inc. Data in Excel

Get Biomerica Inc. Data in Excel